• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 - Product Image

Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

  • ID: 2075335
  • February 2012
  • 81 pages
  • GlobalData

FEATURED COMPANIES

  • A.P. Pharma Inc.
  • Aptalis Pharma, Inc.
  • Eisai Co. Ltd
  • Helsinn Healthcare S.A.
  • MORE

Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, “Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Chemotherapy induced Nausea and Vomiting Therapeutics market. The report identifies the key trends shaping and driving the global Chemotherapy induced Nausea and Vomiting Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Chemotherapy induced Nausea and Vomiting Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers READ MORE >

FEATURED COMPANIES

  • A.P. Pharma Inc.
  • Aptalis Pharma, Inc.
  • Eisai Co. Ltd
  • Helsinn Healthcare S.A.
  • MORE

1
1

1.1 List of Tables
1.2 List of Figures
2 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Introduction
2.1 Overview
2.1.1 Classification of Chemotherapy-Induced Nausea and Vomiting
2.2 Risk factors for Chemotherapy-Induced Nausea and Vomiting
2.3 Epidemiology
2.4 Symptoms
2.5 Etiology
2.6 Pathophysiology
2.7 Diagnosis
2.8 Treatment of Chemotherapy-Induced Nausea and Vomiting
2.8.1 Current Guidelines
2.8.2 Prevention of CINV by Emetogenic Potential of Chemotherapy and Class
2.9 GlobalData Pipeline Report Guidance
3 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Market Characterization
3.1 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Size (2006-2011) - Global
3.2 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Forecast (2011-2019) - Global
3.3 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Size (2006-2011) - the US
3.4 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Forecast (2011-2019) - the US
3.5 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Size (2006-2011) - France
3.6 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Forecast (2011-2019) - France
3.7 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Size (2006-2011) - Germany
3.8 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Forecast (2011-2019) - Germany
3.9 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Size (2006-2011) - Italy
3.10 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Forecast (2011-2019) - Italy
3.11 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Size (2006-2011) - Spain
3.12 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Forecast (2011-2019) - Spain
3.13 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Size (2006-2011) - the UK
3.14 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Forecast (2011-2019) - the UK
3.15 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Size (2006-2011) - Japan
3.16 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Forecast (2011-2019) - Japan
3.17 Drivers and Barriers for the Chemotherapy-Induced Nausea and Vomiting Therapeutics Market
3.17.1 Drivers for the Chemotherapy-Induced Nausea and Vomiting Therapeutics Market
3.17.2 Barriers for the Chemotherapy-Induced Nausea and Vomiting Therapeutics Market
3.18 Key Events Impacting the Future Market
3.19 Opportunity and Unmet Need Analysis
3.19.1 Key Takeaway
4 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for the Major Marketed Products in the Chemotherapy-Induced Nausea and Vomiting Therapeutics Market
4.3.1 Anzemet (dolasetron mesylate)
4.3.2 Kytril (granisetron)
4.3.3 Sancuso (granisetron Transdermal System)
4.3.4 Zuplenz/Zofran (ondansetron)
4.3.5 Aloxi (palonosetron hydrochloride)
4.3.6 Emend (aprepitant/fosaprepitant dimeglumine)
4.4 Key Takeaway
5 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Chemotherapy-Induced Nausea and Vomiting Pipeline - Pipeline by Phases of Development
5.3.1 Chemotherapy-Induced Nausea and Vomiting Therapeutics - Pre-registration Pipeline
5.3.2 Chemotherapy-Induced Nausea and Vomiting Therapeutics - Phase III Pipeline
5.3.3 Chemotherapy-Induced Nausea and Vomiting Therapeutics - Phase II Pipeline
5.3.4 Chemotherapy-Induced Nausea and Vomiting Therapeutics - Phase I Pipeline
5.3.5 Chemotherapy-Induced Nausea and Vomiting Therapeutics - Preclinical
5.3.6 Chemotherapy-Induced Nausea and Vomiting Therapeutics - Discovery
5.4 Chemotherapy-Induced Nausea and Vomiting Therapeutics - Pipeline by Mechanism of Action
5.5 Chemotherapy-Induced Nausea and Vomiting Technology Trends Analytical Framework
5.6 Molecule Profile for Key Late Stage Drugs under Clinical Development
5.6.1 APF530
5.6.2 EUR-1025
5.6.3 Netupitant
5.7 Key takeaway
6 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (the US, EU5 and Japan)
6.2 Clinical Trials Mapping by Phase
6.3 Clinical Trials Mapping by Trial Status
6.4 Overall Sponsors
6.5 Prominent Sponsors
6.6 Top Companies Participating in Chemotherapy-Induced Nausea and Vomiting Therapeutics Clinical Trials
7 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Strategic Assessment
7.1 Chemotherapy-Induced Nausea and Vomiting Therapeutics - Implications for Future Market Competition
8 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 A.P. Pharma Inc.
8.2.2 Aptalis Pharma, Inc.
8.2.3 Eisai Co. Ltd
8.2.4 Helsinn Healthcare S.A.
9 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Licensing and Partnership Deals
10 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Appendix
10.1 Definitions
10.2 Acronyms
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: Chemotherapy Induced Nausea and Vomiting, Emetic Risk Levels of Major Chemotherapeutic Agents
Table 2: Chemotherapy-Induced Nausea and Vomiting, Marketed Drugs
Table 3: CINV Therapeutics Market, Global, Forecast ($m), 2006 - 2011
Table 4: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Global, Forecast ($bn), 2011 - 2019
Table 5: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, the US, Revenue ($m), 2006 - 2011
Table 6: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, the US, Forecast ($m), 2011 - 2019
Table 7: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, France, Revenue ($m), 2006 - 2011
Table 8: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, France, Forecast ($m), 2011 - 2019
Table 9: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Germany, Revenue ($m), 2006 - 2011
Table 10: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Germany, Forecast ($m), 2011 - 2019
Table 11: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Italy, Revenue ($m), 2006 - 2011
Table 12: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Italy, Forecast ($m), 2011 - 2019
Table 13: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Spain, Revenue ($m), 2006 - 2011
Table 14: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Spain, Forecast ($m), 2011 - 2019
Table 15: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, the UK, Revenue ($m), 2006 - 2011
Table 16: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, the UK, Forecast ($m), 2011 - 2019
Table 17: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Japan, Revenue ($m), 2006 - 2011
Table 18: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Japan, Forecast ($m), 2011 - 2019
Table 19: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Pre-registration Pipeline, 2011
Table 20: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Phase III Pipeline, 2011
Table 21: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Phase II Pipeline, 2011
Table 22: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Phase I Pipeline, 2011
Table 23: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Preclinical Pipeline, 2011
Table 24: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Discovery Pipeline, 2011
Table 25: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Clinical Trials by Country, 2011
Table 26: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Clinical Trials by Phase, 2011
Table 27: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Clinical Trials by Status, 2011
Table 28: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Overall Sponsors, 2011
Table 29: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Prominent Sponsors, 2011
Table 30: Chemotherapy-Induced Nausea and Vomiting Therapeutics Clinical Trial - Company Sponsors by Phase, 2011
Table 31: A.P. Pharma - Chemotherapy-Induced Nausea and Vomiting Pipeline
Table 32: Aptalis Pharma - Chemotherapy-Induced Nausea and Vomiting Pipeline
Table 33: Eisai Co. Ltd - Chemotherapy-Induced Nausea and Vomiting Pipeline
Table 34: Helsinn Healthcare S.A. - Chemotherapy-Induced Nausea and Vomiting Pipeline
Table 35: Chemotherapy-Induced Nausea and Vomiting Therapeutics, Global, Deals

1.2 List of Figures
Figure 1: Chemotherapy Induced Nausea and Vomiting, Classification and Risk Factors, 2011
Figure 2: Chemotherapy-Induced Nausea and Vomiting Risk Factors
Figure 3: Systems involved in Pathophysiology of Chemotherapy-Induced Nausea and Vomiting
Figure 4: Pathophysiology of Chemotherapy-Induced Nausea and Vomiting
Figure 5: Chemotherapy-Induced Nausea and Vomiting Therapeutics, Alignment of Recommendations
Figure 6: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Global, Revenue ($bn), 2006 - 2011
Figure 7: Chemotherapy-Induced Nausea and Vomiting Therapeutics, Market Share ($m, %), 2011
Figure 8: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Global, Forecast ($bn), 2011 - 2019
Figure 9: Chemotherapy-Induced Nausea and Vomiting Therapeutics, Market Share ($m, %), 2019
Figure 10: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, the US, Revenue ($m), 2006 - 2011
Figure 11: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, the US, Forecast ($m), 2011 - 2019
Figure 12: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, France, Revenue ($m), 2006 - 2011
Figure 13: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, France, Forecast ($m), 2011 - 2019
Figure 14: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Germany, Revenue ($m), 2006 - 2011
Figure 15: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Germany, Forecast ($m), 2011 - 2019
Figure 16: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Italy, Revenue ($m), 2006 - 2011
Figure 17: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Italy, Forecast ($m), 2011 - 2019
Figure 18: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Spain, Revenue ($m), 2006 - 2011
Figure 19: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Spain, Forecast ($m), 2011 - 2019
Figure 20: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, the UK, Revenue ($m), 2006 - 2011
Figure 21: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, the UK, Forecast ($m), 2011 - 2019
Figure 22: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Japan, Revenue ($m), 2006 - 2011
Figure 23: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Japan, Forecast ($m), 2011 - 2019
Figure 24: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Drivers and Barriers, 2011
Figure 25: Chemotherapy-Induced Nausea and Vomiting Therapeutics, Opportunity and Unmet Need, 2011
Figure 26: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Strategic Competitor Assessment, 2011
Figure 27: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Pipeline by Phase of Clinical Development, 2011
Figure 28: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Clinical Pipeline by Mechanism Of Action, 2011
Figure 29: Chemotherapy-Induced Nausea and Vomiting Therapeutics, Technology Trends Analytical Framework, , 2011
Figure 30: Chemotherapy-Induced Nausea and Vomiting Therapeutics, Technology Trends Analytical Framework, Description, 2011
Figure 31: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Clinical Trials by Country, 2011
Figure 32: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Clinical Trials by Phase, 2011
Figure 33: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Clinical Trials by Status, 2011
Figure 34: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Overall Sponsors, 2011
Figure 35: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Clinical trials by Prominent Sponsors, 2011
Figure 36: Chemotherapy-Induced Nausea and Vomiting Therapeutics Clinical Trial - Company Sponsors by Phase, 2011
Figure 37: Chemotherapy-Induced Nausea and Vomiting Therapeutics, Strategic Assessment, 2011
Figure 38: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Pipeline by Company, 2011

FEATURED COMPANIES

  • A.P. Pharma Inc.
  • Aptalis Pharma, Inc.
  • Eisai Co. Ltd
  • Helsinn Healthcare S.A.
  • MORE

No novel drugs for treating nausea for cancer patients are expected to be launched in the near future

Cancer patients suffering from chemotherapy-induced nausea and vomiting (CINV) will have to wait for the pharmaceuticals market to catch up with their needs, new drug research from industry analysis specialist GlobalData has found.

The study found that the CINV drug developmental pipeline is weak due to a lack of novel molecules. The developmental pipeline for CINV consists of 12 molecules in various stages of development. However, the majority of the pipeline molecules are merely product extensions or new formulations of existing drugs, and the one molecule offering a novel mechanism of action is in the very early stages of development. The lack of a strong developmental pipeline is expected to not only disappoint clinicians and patients, but also leads to the slow growth of the CINV therapeutics market for at least the next decade.

Due to its weak product pipeline, GlobalData estimates that the value of the CINV therapeutics market is forecast to show the moderate growth in the next eight years, reaching a value of US$1.8 billion by 2019. This is due to the patent expiries of Aloxi and Emend, and the subsequent launch of generics in the forecast period.

The global CINV therapeutics market was found to be worth US$1.2 billion in 2011 and grew at a compound annual growth rate (CAGR) of 6.1% from $892m in 2006.

During this period, the market experienced a high uptake of premium, high-cost antiemetics such as Aloxi (palonosetron) and Emend (aprepitant). The launches of Emend and Promend (fosaprepitant) in Japan in 2009 and 2011 respectively also contributed to market growth during this period.

The situation may begin to improve for cancer sufferers, as pharmaceutical companies will need to focus on compliance with patient needs if they are to succeed in capturing market share from the current leaders. While some clinicians would argue that the current marketed products for CINV offer a high efficacy, safety and affordability, others say that up to 80% of cases of CINV could be eliminated if pharmaceuticals companies increased their investment in research and clinical trials.

Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

The report is an essential source of information and analysis on the global chemotherapy-induced nausea and vomiting (CINV) market. The report identifies the key trends shaping and driving the global CINV market, and provides insight into the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global CINV sector.

A.P. Pharma Inc.
Aptalis Pharma, Inc.
Eisai Co. Ltd
Helsinn Healthcare S.A.

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos